Literature DB >> 14555499

Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003.

Yun Yen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14555499

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  7 in total

1.  Ddb1 controls genome stability and meiosis in fission yeast.

Authors:  Christian Holmberg; Oliver Fleck; Heidi A Hansen; Cong Liu; Rita Slaaby; Antony M Carr; Olaf Nielsen
Journal:  Genes Dev       Date:  2005-04-01       Impact factor: 11.361

2.  Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.

Authors:  Dharmika S P Lansakara-P; B Leticia Rodriguez; Zhengrong Cui
Journal:  Int J Pharm       Date:  2012-03-16       Impact factor: 5.875

3.  Evaluating the therapeutic potential of a non-natural nucleotide that inhibits human ribonucleotide reductase.

Authors:  Md Faiz Ahmad; Qun Wan; Shalini Jha; Edward Motea; Anthony Berdis; Chris Dealwis
Journal:  Mol Cancer Ther       Date:  2012-08-28       Impact factor: 6.261

4.  A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.

Authors:  Do-Youn Oh; Keun Wook Lee; Kyung-Hee Lee; Chang-Hak Sohn; Young Suk Park; Dae Young Zang; Hun-Mo Ryoo; Hong-Suk Song; Jin-Soo Kim; Hye-Jin Kang; Bong-Seog Kim; Yung-Jue Bang
Journal:  Invest New Drugs       Date:  2011-03-15       Impact factor: 3.850

5.  Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.

Authors:  Motofumi Tanaka; Milind Javle; Xiaoqun Dong; Cathy Eng; James L Abbruzzese; Donghui Li
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

6.  The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.

Authors:  Ying-Fang Su; Tzu-Fan Wu; Jiunn-Liang Ko; Hsiu-Ting Tsai; Yi-Torng Tee; Ming-Hsien Chien; Chi-Hung Chou; Wea-Lung Lin; Hui-Ying Low; Ming-Yung Chou; Shun-Fa Yang; Po-Hui Wang
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

7.  Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer.

Authors:  Y-Y Hsieh; C-J Chou; H-L Lo; P-M Yang
Journal:  Cell Death Discov       Date:  2016-05-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.